CLINICAL TRIALS PROFILE FOR MYCIFRADIN

All Clinical Trials for MYCIFRADIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00945334 ↗	Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome	Completed	Bausch Health Americas, Inc.	N/A	2009-08-01	In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test. This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.
NCT00945334 ↗	Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome	Completed	Valeant Pharmaceuticals International, Inc.	N/A	2009-08-01	In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test. This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.
NCT00945334 ↗	Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome	Completed	Mark Pimentel, MD	N/A	2009-08-01	In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test. This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.
NCT03557008 ↗	Systems Biology of Inactivated Rabies Vaccine in Healthy Adults With or Without Use of Broad Spectrum Antibiotics	Active, not recruiting	Emory University	Phase 4	2018-07-05	The study is a prospective randomized, unblinded study looking to enroll 54 subjects at Emory University. The use of antibiotics changes micro-organisms in the intestines. The change to micro-organisms in the intestines may change the body's vaccine immune response and alter the effectiveness of the rabies vaccine. There will be two randomized groups (1:1 randomization). Group A will start taking an antibiotic regimen by mouth 3 days prior to vaccination and continue taking antibiotics the day of rabies vaccination and one day after vaccination for a total of 5 days. Group B will only receive the rabies vaccination and will not take any antibiotics. The dosage of each antibiotic is taken from their respective package inserts and does not exceed the maximum dose allowed for each antibiotic. The purpose of the study is to look at certain markers (immune responses) in blood and lymph nodes after rabies vaccination with or without the use of antibiotics from day of vaccination to 28 days post vaccination in both groups.

Clinical Trial Conditions for MYCIFRADIN

Condition Name

Condition Name for MYCIFRADIN
Intervention	Trials
Constipation-predominant Irritable Bowel Syndrome	1
Rabies Human	1

Condition MeSH

Condition MeSH for MYCIFRADIN
Intervention	Trials
Rabies	1
Syndrome	1
Irritable Bowel Syndrome	1
Constipation	1

Clinical Trial Locations for MYCIFRADIN

Trials by Country

Trials by Country for MYCIFRADIN
Location	Trials
United States	3

Trials by US State

Trials by US State for MYCIFRADIN
Location	Trials
Georgia	2
California	1

Clinical Trial Progress for MYCIFRADIN

Clinical Trial Phase

Clinical Trial Phase for MYCIFRADIN
Clinical Trial Phase	Trials
Phase 4	1
N/A	1

Clinical Trial Status

Clinical Trial Status for MYCIFRADIN
Clinical Trial Phase	Trials
Active, not recruiting	1
Completed	1

Clinical Trial Sponsors for MYCIFRADIN

Sponsor Name

Sponsor Name for MYCIFRADIN
Sponsor	Trials
Emory University	1
Bausch Health Americas, Inc.	1
Valeant Pharmaceuticals International, Inc.	1

Sponsor Type

Sponsor Type for MYCIFRADIN
Sponsor	Trials
Other	2
Industry	2